Strategic collaboration always makes good business sense. You need allies to win wars, and management teams should use military principles to overcome market entry barriers. Anadis (OTC:ANDIY) is a tempting stock from the distant but friendly continent of Australia, available for trading in the US. The word ‘influenza’ and all its popular forms such as ’flu’ strike terror in all hearts, and shortages of vaccines have become irritants in our entire health care system. Anadis (OTC:ANDIY) must be a winner, going by early results of its novel mode of protection against some virus attacks.
‘Early’ is the operative word in that last sentence! The business of preventive medicine goes through a tortuous regulatory process, and only a small number of candidate new products make it to market. Viruses can change form, so the Centers of Disease Control and Prevention in Atlanta have come up with new vaccine products every year. Anadis (OTC:ANDIY) has the requisite biological materials from its interests in dairy animals, to develop a continuous stream of new agents to fight viruses, but how good is it at clinical trials, scaling up production, and logistics?
An established management template of bringing new discoveries to the US health care market is that of Mergers and Acquisitions. Large pharmaceutical corporations routinely associate with niche laboratory operations, resulting in enormous benefits for all stakeholders. Making it to market alone was the norm in the early 20th century, but it is nearly impossible now, at least from the stock investment perspective. Overall, OTC:ANDIY would rank at the top of stock picks the management works on a strategic partner to make dividends quickly and reliably from their fascinating discoveries.
Let us hear your thoughts below:
